These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 17015838)

  • 41. Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53.
    Joerger AC; Bauer MR; Wilcken R; Baud MGJ; Harbrecht H; Exner TE; Boeckler FM; Spencer J; Fersht AR
    Structure; 2015 Dec; 23(12):2246-2255. PubMed ID: 26636255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutational analysis of the p53 core domain L1 loop.
    Zupnick A; Prives C
    J Biol Chem; 2006 Jul; 281(29):20464-73. PubMed ID: 16687402
    [TBL] [Abstract][Full Text] [Related]  

  • 43. p53 mutants without a functional tetramerisation domain are not oncogenic.
    Chène P; Bechter E
    J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation".
    Friedler A; DeDecker BS; Freund SM; Blair C; Rüdiger S; Fersht AR
    J Mol Biol; 2004 Feb; 336(1):187-96. PubMed ID: 14741214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
    Cho Y; Gorina S; Jeffrey PD; Pavletich NP
    Science; 1994 Jul; 265(5170):346-55. PubMed ID: 8023157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
    Rippin TM; Bykov VJ; Freund SM; Selivanova G; Wiman KG; Fersht AR
    Oncogene; 2002 Mar; 21(14):2119-29. PubMed ID: 11948395
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural evolution of p53, p63, and p73: implication for heterotetramer formation.
    Joerger AC; Rajagopalan S; Natan E; Veprintsev DB; Robinson CV; Fersht AR
    Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17705-10. PubMed ID: 19815500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation.
    Ashur-Fabian O; Avivi A; Trakhtenbrot L; Adamsky K; Cohen M; Kajakaro G; Joel A; Amariglio N; Nevo E; Rechavi G
    Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12236-41. PubMed ID: 15302922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
    Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factors governing loss and rescue of DNA binding upon single and double mutations in the p53 core domain.
    Wright JD; Noskov SY; Lim C
    Nucleic Acids Res; 2002 Apr; 30(7):1563-74. PubMed ID: 11917017
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dynamics and Molecular Mechanisms of p53 Transcriptional Activation.
    Offutt TL; Ieong PU; Demir Ö; Amaro RE
    Biochemistry; 2018 Nov; 57(46):6528-6537. PubMed ID: 30388364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants.
    Demir Ö; Baronio R; Salehi F; Wassman CD; Hall L; Hatfield GW; Chamberlin R; Kaiser P; Lathrop RH; Amaro RE
    PLoS Comput Biol; 2011 Oct; 7(10):e1002238. PubMed ID: 22028641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
    Kong XT; Gao H; Stanbridge EJ
    J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.
    Stavridi ES; Chehab NH; Caruso LC; Halazonetis TD
    Protein Sci; 1999 Sep; 8(9):1773-9. PubMed ID: 10493578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
    Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
    Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural biology of the tumor suppressor p53.
    Joerger AC; Fersht AR
    Annu Rev Biochem; 2008; 77():557-82. PubMed ID: 18410249
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Wrapping effects within a proposed function-rescue strategy for the Y220C oncogenic mutation of protein p53.
    Accordino SR; Rodríguez Fris JA; Appignanesi GA
    PLoS One; 2013; 8(1):e55123. PubMed ID: 23365691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding.
    Babikir HA; Afjei R; Paulmurugan R; Massoud TF
    Cancer Treat Rev; 2018 Dec; 71():19-31. PubMed ID: 30336366
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thermodynamic stability of wild-type and mutant p53 core domain.
    Bullock AN; Henckel J; DeDecker BS; Johnson CM; Nikolova PV; Proctor MR; Lane DP; Fersht AR
    Proc Natl Acad Sci U S A; 1997 Dec; 94(26):14338-42. PubMed ID: 9405613
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [P53 at the atomic scale: the multiple faces of a crystal].
    Hainaut P
    Bull Cancer; 1997 Jul; 84(7):747-51. PubMed ID: 9339202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.